<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00096499</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02630</org_study_id>
    <secondary_id>SWOG-S0418</secondary_id>
    <secondary_id>U10CA032102</secondary_id>
    <secondary_id>CDR0000393206</secondary_id>
    <nct_id>NCT00096499</nct_id>
  </id_info>
  <brief_title>SB-715992 in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Docetaxel or Paclitaxel</brief_title>
  <official_title>A Phase II Study of SB-715992 (NSC-727990, IND-70273) in Taxane-Resistant Androgen-Independent Metastatic Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      Drugs used in chemotherapy, such as SB-715992, work in different ways to stop tumor cells&#xD;
      from dividing so they stop growing or die. This phase II trial is studying how well SB-715992&#xD;
      works in treating patients with metastatic prostate cancer that did not respond to docetaxel&#xD;
      or paclitaxel&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the prostate-specific antigen response to SB-715992 in patients with&#xD;
      hormone-refractory, androgen-independent metastatic prostate cancer that failed prior&#xD;
      taxane-based chemotherapy.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the median overall survival and median progression-free survival of patients&#xD;
      treated with this drug.&#xD;
&#xD;
      II. Determine the objective response rate (confirmed and unconfirmed, complete and partial&#xD;
      response) in patients with measurable disease treated with this drug.&#xD;
&#xD;
      III. Determine the qualitative and quantitative toxic effects of this drug in these patients.&#xD;
&#xD;
      IV. Determine, preliminarily, the pharmacokinetics and mechanism of activity of this drug in&#xD;
      these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive SB-715992 IV over 1 hour on day 1. Courses repeat every 21 days in the&#xD;
      absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients are followed every 3 months for 1 year and then every 6 months for 2 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 20-40 patients will be accrued for this study within 1.3-2.7&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2005</start_date>
  <primary_completion_date type="Actual">January 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Probability of PSA response</measure>
    <time_frame>Up to 3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From date of registration to date of death due to any cause, assessed up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>From date of registration to date of first observation of progressive disease, symptomatic deterioration, or death due to any cause, assessed up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Probability of objective response</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Adenocarcinoma of the Prostate</condition>
  <condition>Recurrent Prostate Cancer</condition>
  <condition>Stage IV Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment (ispinesib)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive SB-715992 IV over 1 hour on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ispinesib</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (ispinesib)</arm_group_label>
    <other_name>CK0238273</other_name>
    <other_name>SB-715992</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (ispinesib)</arm_group_label>
    <other_name>pharmacological studies</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (ispinesib)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma of the prostate&#xD;
&#xD;
               -  Metastatic disease (N1 and/or M1)&#xD;
&#xD;
               -  Unresponsive or refractory to androgen-deprivation therapy&#xD;
&#xD;
          -  Must have received one, and only one, prior taxane-containing (docetaxel or&#xD;
             paclitaxel) chemotherapy regimen for metastatic disease that was discontinued due to&#xD;
             disease progression, intolerance, or patient request&#xD;
&#xD;
          -  Evidence of disease progression as defined by ≥ 1 of the following:&#xD;
&#xD;
               -  Progression of measurable disease&#xD;
&#xD;
               -  Progression of evaluable disease&#xD;
&#xD;
               -  Rising prostate-specific antigen (PSA)&#xD;
&#xD;
                    -  At least 2 consecutive rises in PSA levels, each taken ≥ 7 days apart&#xD;
&#xD;
                    -  PSA ≥ 5 ng/mL&#xD;
&#xD;
          -  Must have pre-study PSA &gt; 5 ng/mL&#xD;
&#xD;
          -  Measurable or evaluable disease&#xD;
&#xD;
               -  Soft tissue disease that has been irradiated within the past 2 months is not&#xD;
                  considered measurable disease&#xD;
&#xD;
               -  Soft tissue disease that has been irradiated ≥ 2 months prior to study entry is&#xD;
                  considered measurable disease provided the lesion progressed after radiation&#xD;
&#xD;
          -  Surgical or medical castration required&#xD;
&#xD;
               -  If luteinizing hormone-releasing hormone (LHRH) agonists (leuprolide or&#xD;
                  goserelin) or LHRH antagonists (abarelix) were used, then must continue use&#xD;
                  during study therapy&#xD;
&#xD;
          -  No prior or concurrent brain metastases (treated or untreated)&#xD;
&#xD;
               -  If clinical suspicion of brain metastases, must meet the following criteria:&#xD;
&#xD;
                    -  Brain CT scan or MRI negative for metastatic disease within the past 56 days&#xD;
&#xD;
                    -  No new symptoms since radiographic evaluation&#xD;
&#xD;
          -  Performance status - Zubrod 0-2&#xD;
&#xD;
          -  Absolute granulocyte count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 9 g/dL&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  SGOT and SGPT ≤ 2.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Creatinine ≤ 1.5 times ULN&#xD;
&#xD;
          -  Creatinine clearance ≥ 40 mL/min&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No cardiac arrhythmia&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No peripheral neuropathy ≥ grade 2&#xD;
&#xD;
          -  No prior allergic reaction attributed to compounds of similar chemical or biological&#xD;
             composition to SB-715992&#xD;
&#xD;
          -  No ongoing or active infection&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study participation&#xD;
&#xD;
          -  No other uncontrolled illness&#xD;
&#xD;
          -  No other malignancy within the past 5 years except adequately treated basal cell or&#xD;
             squamous cell skin cancer or adequately treated stage I or II cancer in complete&#xD;
             remission&#xD;
&#xD;
          -  No colony-stimulating factors during the first course of study therapy&#xD;
&#xD;
          -  No concurrent anticancer biologic therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy and recovered&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior flutamide or ketoconazole&#xD;
&#xD;
          -  At least 6 weeks since prior bicalutamide or nilutamide&#xD;
&#xD;
          -  No concurrent anticancer hormonal therapy except LHRH agonist or antagonist for&#xD;
             patients who have not undergone orchiectomy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy and recovered&#xD;
&#xD;
          -  Prior samarium Sm 153 lexidronam pentasodium allowed&#xD;
&#xD;
          -  No prior strontium chloride Sr 89&#xD;
&#xD;
          -  No prior radiotherapy to ≥ 30% of bone marrow&#xD;
&#xD;
          -  No concurrent anticancer radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 3 weeks since prior surgery and recovered&#xD;
&#xD;
          -  At least 2 weeks since prior and no concurrent use of any of the following CYP3A4&#xD;
             inhibitors or inducers:&#xD;
&#xD;
               -  Clarithromycin&#xD;
&#xD;
               -  Erythromycin&#xD;
&#xD;
               -  Troleandomycin&#xD;
&#xD;
               -  Rifampin&#xD;
&#xD;
               -  Rifabutin&#xD;
&#xD;
               -  Rifapentine&#xD;
&#xD;
               -  Itraconazole&#xD;
&#xD;
               -  Ketoconazole&#xD;
&#xD;
               -  Fluconazole (dose &gt; 200 mg/day)&#xD;
&#xD;
               -  Voriconazole&#xD;
&#xD;
               -  Nefazodone&#xD;
&#xD;
               -  Fluvoxamine&#xD;
&#xD;
               -  Verapamil&#xD;
&#xD;
               -  Diltiazem&#xD;
&#xD;
               -  Grapefruit juice&#xD;
&#xD;
               -  Bitter orange&#xD;
&#xD;
               -  Phenytoin&#xD;
&#xD;
               -  Carbamazepine&#xD;
&#xD;
               -  Phenobarbital&#xD;
&#xD;
               -  Oxcarbazepine&#xD;
&#xD;
               -  Hypericum perforatum (St. John's wort)&#xD;
&#xD;
               -  Modafinil&#xD;
&#xD;
          -  At least 6 months since prior and no concurrent amiodarone&#xD;
&#xD;
          -  No other investigational drugs for 4 weeks before, during, and for 2 weeks after study&#xD;
             therapy&#xD;
&#xD;
          -  No other concurrent anticancer cytotoxic therapy&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
&#xD;
          -  No concurrent combination antiretroviral therapy for HIV-positive patients&#xD;
&#xD;
          -  Concurrent enrollment on SWOG-9205 (central prostate cancer serum repository protocol)&#xD;
             allowed&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tomasz Beer</last_name>
    <role>Principal Investigator</role>
    <affiliation>Southwest Oncology Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Southwest Oncology Group</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78245</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>November 9, 2004</study_first_submitted>
  <study_first_submitted_qc>November 9, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2004</study_first_posted>
  <last_update_submitted>January 24, 2013</last_update_submitted>
  <last_update_submitted_qc>January 24, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

